Study of Ablation-Index Guided Scar-Related Ventricular Tachycardia Treatment in Patients with Ischemic Cardiomyopathy Randomized Trial Comparing AI-Guided vs Standard Ablation Procedures

What this Trial Is About

Researchers are evaluating the use of Ablation Index AI guidance during radiofrequency catheter ablation RFCA for ventricular tachycardia VT in patients with ischemic cardiomyopathy and prior myocardial infarction. This study aims to test whether AI guidance can shorten the procedural duration compared to conventional ablation methods. The study focuses on improving lesion quality by incorporating power, contact force, and time to better estimate lesion depth during VT ablation in patients with structural heart disease. Participants will be randomly assigned to one of two groups one receiving VT ablation guided by the Ablation Index and the other undergoing ablation without AI guidance, where AI values are masked from the operator. The AI incorporates power delivery combined with contact force and time to provide a weighted estimate of lesion quality, aiming to improve ablation precision. This trial is single-blinded and multicenter, focusing on procedural duration and safety. During the study, participants will undergo VT ablation with monitoring of procedural parameters like ablation time, total procedure duration, intravenous fluid use, and fluoroscopy time. Researchers will assess the percentage reduction in ablation time between the AI-guided and non-AI-guided groups. The study will also monitor safety and procedural efficiency. Participant involvement includes follow-up assessments as required until the study completion date in November 2027.

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy